US equities |
SPCX $171.09 ▲+0.00% MU $1,063.96 ▲+0.00% NVDA $238.90 ▲+0.00% META $741.90 ▲+0.00% AMD $631.75 ▲+0.00% AMZN $251.40 ▲+0.00% SNDK $1,704.16 ▲+0.00% INTC $116.19 ▲+0.00%
FinancialContent

Articles published by Reneo Pharmaceuticals, Inc.

News headline image
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Announces Pricing of Public Offering of Common Stock
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM
News headline image
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
From Reneo Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RPHM